Literature DB >> 21393333

Prognostic value of the International Scoring System and response in patients with advanced Waldenstrom macroglobulinemia.

Bénédicte Hivert, Jérome Tamburini, Anne Vekhoff, Olivier Tournilhac, Véronique Leblond, Pierre Morel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21393333      PMCID： PMC3084930          DOI： 10.3324/haematol.2010.029140

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  11 in total

1.  Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.

Authors:  Vincent Lévy; Pierre Morel; Raphaël Porcher; Sylvie Chevret; Eric Wattel; Véronique Leblond
Journal:  Haematologica       Date:  2005-02       Impact factor: 9.941

2.  International prognostic scoring system for Waldenstrom macroglobulinemia.

Authors:  Pierre Morel; Alain Duhamel; Paolo Gobbi; Meletios A Dimopoulos; Madhav V Dhodapkar; Jason McCoy; John Crowley; Enrique M Ocio; Ramon Garcia-Sanz; Steven P Treon; Veronique Leblond; Robert A Kyle; Bart Barlogie; Giampaolo Merlini
Journal:  Blood       Date:  2009-02-05       Impact factor: 22.113

3.  Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia.

Authors:  Steven P Treon; Andrew R Branagan; Leukothea Ioakimidis; Jacob D Soumerai; Christopher J Patterson; Barry Turnbull; Parveen Wasi; Christos Emmanouilides; Stanley R Frankel; Andrew Lister; Pierre Morel; Jeffrey Matous; Stephanie A Gregory; Eva Kimby
Journal:  Blood       Date:  2008-11-17       Impact factor: 22.113

4.  Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial.

Authors:  Morie A Gertz; Rafat Abonour; Leonard T Heffner; Philip R Greipp; Hajime Uno; S V Rajkumar
Journal:  Br J Haematol       Date:  2009-09-14       Impact factor: 6.998

5.  Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia.

Authors:  Eva Kimby; Steven P Treon; Athanasios Anagnostopoulos; Meletios Dimopoulos; Ramon Garcia-Sanz; Morie A Gertz; Stephen Johnson; Veronique LeBlond; Jean-Paul Fermand; David G Maloney; Giampaolo Merlini; Pierre Morel; Enrica Morra; Gwen Nichols; Enrique M Ocio; Roger Owen; Marvin Stone; Joan Bladé
Journal:  Clin Lymphoma Myeloma       Date:  2006-03

6.  Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies.

Authors:  Constantine Tam; John F Seymour; Michael Brown; Philip Campbell; John Scarlett; Craig Underhill; David Ritchie; Rodney Bond; Andrew P Grigg
Journal:  Haematologica       Date:  2005-05       Impact factor: 9.941

7.  Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.

Authors:  J Tamburini; V Lévy; C Chaleteix; J P Fermand; A Delmer; L Stalniewicz; P Morel; F Dreyfus; M J Grange; B Christian; S Choquet; V Leblond
Journal:  Leukemia       Date:  2005-10       Impact factor: 11.528

8.  Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide.

Authors:  Meletios Athanasios Dimopoulos; Athanasios Anagnostopoulos; Marie-Christine Kyrtsonis; Konstantinos Zervas; Constantinos Tsatalas; Garyfallia Kokkinis; Panagiotis Repoussis; Argyris Symeonidis; Souzana Delimpasi; Eirini Katodritou; Elina Vervessou; Evridiki Michali; Anastasia Pouli; Dimitra Gika; Amalia Vassou; Evangelos Terpos; Nikolaos Anagnostopoulos; Theophanis Economopoulos; Gerasimos Pangalis
Journal:  J Clin Oncol       Date:  2007-06-18       Impact factor: 44.544

9.  Allogeneic hematopoietic stem cell transplantation allows long-term complete remission and curability in high-risk Waldenström’s macroglobulinemia. Results of a retrospective analysis of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Authors:  Alice Garnier; Marie Robin; Fabrice Larosa; Jean-Louis Golmard; Steven Le Gouill; Valérie Coiteux; Reza Tabrizi; Claude-Eric Bulabois; Victoria Cacheux; Mathieu Kuentz; Brigitte Dreyfus; Peter Dreger; Bernard Rio; Marie-Pierre Moles-Moreau; Karin Bilger; Jacques-Olivier Bay; Véronique Leblond; Didier Blaise; Olivier Tournilhac; Nathalie Dhédin
Journal:  Haematologica       Date:  2010-01-15       Impact factor: 9.941

10.  Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.

Authors:  Xavier Leleu; Jacob Soumerai; Aldo Roccaro; Evdoxia Hatjiharissi; Zachary R Hunter; Robert Manning; Bryan T Ciccarelli; Antonio Sacco; Leukothea Ioakimidis; Sophia Adamia; Anne-Sophie Moreau; Christopher J Patterson; Irene M Ghobrial; Steven P Treon
Journal:  J Clin Oncol       Date:  2008-12-08       Impact factor: 44.544
View more
  3 in total

Review 1.  Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Authors:  Meletios A Dimopoulos; Efstathios Kastritis; Roger G Owen; Robert A Kyle; Ola Landgren; Enrica Morra; Xavier Leleu; Ramón García-Sanz; Nikhil Munshi; Kenneth C Anderson; Evangelos Terpos; Irene M Ghobrial; Pierre Morel; David Maloney; Mathias Rummel; Véronique Leblond; Ranjana H Advani; Morie A Gertz; Charalampia Kyriakou; Sheeba K Thomas; Bart Barlogie; Stephanie A Gregory; Eva Kimby; Giampaolo Merlini; Steven P Treon
Journal:  Blood       Date:  2014-07-15       Impact factor: 22.113

2.  Onsets of progression and second treatment determine survival of patients with symptomatic Waldenström macroglobulinemia.

Authors:  Stephanie Guidez; Julien Labreuche; Elodie Drumez; Loic Ysebaert; Jana Bakala; Caroline Delette; Bénédicte Hivert; Caroline Protin; Hervé Declercq; Mélanie Verlay; Jean Pierre Marolleau; Alain Duhamel; Pierre Morel
Journal:  Blood Adv       Date:  2018-11-27

3.  Does early disease progression predict survival after first line-treatment of Waldenström macroglobulinemia?

Authors:  Julien Labreuche; Deborah Assouan; Eric Durot; Cecile Tomowiak; Damien Roos-Weil; Elise Toussaint; Fontanet Bijou; Richard Lemal; Annie Brion; Kamel Laribi; Loic Ysebaert; Alain Duhamel; Pierre Morel
Journal:  Hematol Oncol       Date:  2022-05-01       Impact factor: 4.850
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.